Development of an in vitro Trans-Endothelial-Electrical-Resistance (TEER) system allowing the recording of the electrical impedance of biological barriers
The development of drugs against CNS have one of the highest failure rates because CNS drugs have to cross the blood brain barrier (BBB) before reaching the neural tissue. This complexity is worsened by the fact that there is currently no in vitro system to test simultaneously whether a substance can cross the human BBB and adequately affect the adjacent human neural tissue.
We have developed a device allowing the tissue engineering of an artificial human neurovascular unit (NVU), i.e. an in vitro model comprising both the neural tissue and the BBB. This device allows the simultaneous monitoring of the two components of the model and their pharmacological testing. This innovative solution aims at increasing the success rate of CNS drug development by facilitating and speeding up the drug discovery process and to screen potential neurotoxic molecules present in our environment.
This device combining a system to record simultaneously neuronal activity with a system to measure the blood-brain barrier permeability. A Micro-Electrode Array (MEA) unit allow the electrophysiological recording of neural cultures sitting at the bottom of a standard 24-well plate and a Trans Endothelial Electrical Resistance (TEER) unit allowing the recording of the electrical impedance of a cultured BBB positioned just above.
hepia, University of Applied Sciences and Arts Western Switzerland; HES-SO, Switzerland
Prof. Dr. Luc Stoppini: luc.Stoppini@hesge.ch
hepia, University of Applied Sciences and Arts Western Switzerland
c/o Campus Biotech, chemin des Mines 9, CH-1202 Geneva, Switzerland
Place in the Global Health Lab: